CU23592A1 - Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6 - Google Patents

Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6

Info

Publication number
CU23592A1
CU23592A1 CU20060048A CU20060048A CU23592A1 CU 23592 A1 CU23592 A1 CU 23592A1 CU 20060048 A CU20060048 A CU 20060048A CU 20060048 A CU20060048 A CU 20060048A CU 23592 A1 CU23592 A1 CU 23592A1
Authority
CU
Cuba
Prior art keywords
forms
ghrp
peptide
secretagogo
prevent
Prior art date
Application number
CU20060048A
Other languages
English (en)
Inventor
Castillo Mariela Vazquez
Mola Ernesto Lopez
Alba Jose Suarez
Sosa Manuel Selman-Housein
Nieto Gerardo Enrique Guillen
Vera Danay Cibrian
Acosta Jorge Berlanga
Del Barco Herrera Diana Garcia
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20060048A priority Critical patent/CU23592A1/es
Priority to ES07711099T priority patent/ES2388879T3/es
Priority to EP07711099A priority patent/EP1994939B1/en
Priority to JP2008556642A priority patent/JP5426175B2/ja
Priority to PCT/CU2007/000005 priority patent/WO2007098715A1/es
Priority to DK07711099.7T priority patent/DK1994939T3/da
Priority to AU2007219568A priority patent/AU2007219568B2/en
Priority to CN2007800140575A priority patent/CN101426517B/zh
Priority to EP11170318A priority patent/EP2368563A1/en
Priority to MX2008011140A priority patent/MX2008011140A/es
Priority to RU2008138561/15A priority patent/RU2465913C2/ru
Priority to CA2644431A priority patent/CA2644431C/en
Priority to US12/281,018 priority patent/US20090221512A1/en
Priority to KR1020087023744A priority patent/KR101462077B1/ko
Priority to BRPI0708349A priority patent/BRPI0708349B8/pt
Priority to ARP070100804A priority patent/AR059644A1/es
Priority to ZA200807600A priority patent/ZA200807600B/xx
Publication of CU23592A1 publication Critical patent/CU23592A1/es
Priority to US13/150,526 priority patent/US8722626B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención se relaciona con un método para prevenir y eliminar los depósitos de material fibrótico patológico en tejidos parenquimatosos internos como hígado, pulmones, esófago, intestino delgado, rinones, vasos sanguíneos, articulaciones, además de formas sistemáticas de fibrosis cutánea de cualquier etiopatogenia. Dicho método consiste en la administración reiterada por vía intramuscular , intatecal, subcutánea o por infiltración, del péptido secretagogo GHRP-6. Este método también elimina el depósito de material amiloideo y hialino en cualquiera de sus formas químicas y manifestaciones tisulares; entre otras del cerebro, cerebelo, vasos sanguíneos, hígado, intestinos, rinones, bazo, páncreas, articulaciones y la piel. De esta forma se corrige la disfunción de células , tejidos y órganos afectados por estos depósitos anormales.
CU20060048A 2006-02-28 2006-02-28 Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6 CU23592A1 (es)

Priority Applications (18)

Application Number Priority Date Filing Date Title
CU20060048A CU23592A1 (es) 2006-02-28 2006-02-28 Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6
MX2008011140A MX2008011140A (es) 2006-02-28 2007-02-23 Composicion farmaceutica conteniendo ghrp-6 capaz de prevenir y eliminar las fibrosis y otras formas de deposito patologico en los tejidos.
RU2008138561/15A RU2465913C2 (ru) 2006-02-28 2007-02-23 Фармацевтическая композиция, содержащая ghrp-6, для предотвращения и устранения фиброза и других патологических отложений в тканях
JP2008556642A JP5426175B2 (ja) 2006-02-28 2007-02-23 線維症及び組織における他の形の病理学的沈着を予防及び除去することができるｇｈｒｐ−６を含む薬剤組成物
PCT/CU2007/000005 WO2007098715A1 (es) 2006-02-28 2007-02-23 Composición farmacéutica conteniendo ghrp-6 capaz de prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos
DK07711099.7T DK1994939T3 (da) 2006-02-28 2007-02-23 Farmaceutisk sammensætning indeholdende GHRP-6 til forebyggelse og eliminering af fibrose og øvrige patologiske deponeringer i væv
AU2007219568A AU2007219568B2 (en) 2006-02-28 2007-02-23 Pharmaceutical composition containing GHRP-6 capable of preventing and eliminating fibrosis and other forms of pathological deposit in tissue
CN2007800140575A CN101426517B (zh) 2006-02-28 2007-02-23 用于预防和消除组织中纤维样和其他病理性沉积的、含ghrp-6的药物组合物
EP11170318A EP2368563A1 (en) 2006-02-28 2007-02-23 Pharmaceutical composition containing GHRP-6 or GHRP-2 or hexarelin to prevent and eliminate fibrosis and other pathological deposits in tissues
ES07711099T ES2388879T3 (es) 2006-02-28 2007-02-23 Composición farmacéutica que contiene GHRP-6 para prevenir y eliminar las fibrosis y otros depósitos patológicos en tejidos
EP07711099A EP1994939B1 (en) 2006-02-28 2007-02-23 Pharmaceutical composition containing GHRP-6 for preventing and eliminating fibrosis and other pathological deposits in tissue
CA2644431A CA2644431C (en) 2006-02-28 2007-02-23 Pharmaceutical composition containing ghrp-6 capable of preventing and eliminating fibrosis and other forms of pathological deposit in tissue
US12/281,018 US20090221512A1 (en) 2006-02-28 2007-02-23 Pharmaceutical composition containing ghrp-6 to prevent and eliminate fibrosis and other pathological deposits in tissues
KR1020087023744A KR101462077B1 (ko) 2006-02-28 2007-02-23 조직에서의 섬유증 및 병리학적 저장부의 다른 형태를 예방하고 방지할 수 있는 ｇｈｒｐ-6을 포함하는 약학적 조성물
BRPI0708349A BRPI0708349B8 (pt) 2006-02-28 2007-02-23 uso do peptídeo secretagogo ghrp-6
ARP070100804A AR059644A1 (es) 2006-02-28 2007-02-27 Composicion farmaceutica conteniendo ghrp -6 capaz de prevenir y eliminar las fibrosis y otras formas de deposito patologico en los tejidos
ZA200807600A ZA200807600B (en) 2006-02-28 2008-09-03 Pharmaceutical composition containing GHRP-6 capable of preventing and elimanting fibrosis and other forms of pathological deposit in tissue
US13/150,526 US8722626B2 (en) 2006-02-28 2011-06-01 Method for controlling fibrosis and other pathological deposits in tissues comprising administering a GHRP-6 composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060048A CU23592A1 (es) 2006-02-28 2006-02-28 Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6

Publications (1)

Publication Number Publication Date
CU23592A1 true CU23592A1 (es) 2010-11-11

Family

ID=37964643

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20060048A CU23592A1 (es) 2006-02-28 2006-02-28 Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6

Country Status (16)

Country Link
US (2) US20090221512A1 (es)
EP (2) EP2368563A1 (es)
JP (1) JP5426175B2 (es)
KR (1) KR101462077B1 (es)
CN (1) CN101426517B (es)
AR (1) AR059644A1 (es)
AU (1) AU2007219568B2 (es)
BR (1) BRPI0708349B8 (es)
CA (1) CA2644431C (es)
CU (1) CU23592A1 (es)
DK (1) DK1994939T3 (es)
ES (1) ES2388879T3 (es)
MX (1) MX2008011140A (es)
RU (1) RU2465913C2 (es)
WO (1) WO2007098715A1 (es)
ZA (1) ZA200807600B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101623985B1 (ko) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
DK2603600T3 (da) 2010-08-13 2019-03-04 Aileron Therapeutics Inc Peptidomimetiske makrocyklusser
US9096684B2 (en) 2011-10-18 2015-08-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
AU2013221432B2 (en) 2012-02-15 2018-01-18 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR101667383B1 (ko) * 2012-03-28 2016-10-18 주식회사 인코스팜 비오틴이 결합된 ｈｅｘａｐｅｐｔｉｄｅ-２ 유도체 및 이의 용도
MX2015005244A (es) 2012-11-01 2015-07-14 Aileron Therapeutics Inc Aminoacidos disustituidos y metodos de preparacion y el uso de los mismos.
KR102051433B1 (ko) * 2013-08-27 2020-01-08 (주)네오팜 근육 분화 촉진 및 근육 강화용 조성물 및 외용제
US9119832B2 (en) * 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
FR3034662B1 (fr) 2015-04-10 2020-08-28 Isp Investments Inc Nouvelles utilisations du peptide de sequence his-d-trp-ala-trp-d-phe-lys-nh2 pour diminuer ou retarder l'apparition de la senescence cellulaire et des signes du vieillissement cutane
WO2017114316A1 (zh) * 2015-12-30 2017-07-06 南京中硼联康医疗科技有限公司 用于消除β淀粉样蛋白的中子捕获治疗系统
CN109908331A (zh) * 2019-04-30 2019-06-21 青岛大学附属医院 海沙瑞林在制备保护肾脏缺血再灌注损伤药物/药物组合物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
DE60022683D1 (de) * 1999-12-28 2005-10-20 Kaken Pharma Co Ltd Nervenschutzmittel
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
WO2003047624A1 (en) * 2001-12-07 2003-06-12 Kaken Pharmaceutical Co., Ltd. Cell migration inhibitor
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
ES2383685T3 (es) * 2003-04-30 2012-06-25 Kenji Kangawa Preventivos o remedios para hepatopatía
JP2005239712A (ja) * 2004-01-30 2005-09-08 Kaken Pharmaceut Co Ltd 神経突起伸展剤
US20090149512A1 (en) * 2004-05-14 2009-06-11 Novo Nordisk A/S Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases

Also Published As

Publication number Publication date
RU2008138561A (ru) 2010-04-10
CN101426517A (zh) 2009-05-06
US8722626B2 (en) 2014-05-13
ZA200807600B (en) 2009-06-24
DK1994939T3 (da) 2012-09-10
AU2007219568B2 (en) 2012-10-04
JP2009528302A (ja) 2009-08-06
BRPI0708349B8 (pt) 2021-05-25
MX2008011140A (es) 2008-09-08
EP1994939A1 (en) 2008-11-26
US20090221512A1 (en) 2009-09-03
RU2465913C2 (ru) 2012-11-10
ES2388879T3 (es) 2012-10-19
US20110230415A1 (en) 2011-09-22
KR101462077B1 (ko) 2014-11-20
EP1994939B1 (en) 2012-05-30
BRPI0708349A2 (pt) 2011-05-24
WO2007098715A1 (es) 2007-09-07
EP2368563A1 (en) 2011-09-28
BRPI0708349B1 (pt) 2019-04-24
KR20080100378A (ko) 2008-11-17
JP5426175B2 (ja) 2014-02-26
AU2007219568A1 (en) 2007-09-07
CN101426517B (zh) 2013-04-03
CA2644431A1 (en) 2007-09-07
AR059644A1 (es) 2008-04-16
CA2644431C (en) 2016-08-30

Similar Documents

Publication Publication Date Title
CU23592A1 (es) Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6
DOP2021000197A (es) Composición farmacéutica, que comprende la variante de hialuronidasa ph20 humana y fármaco, para inyección subcutánea
CO2021004966A2 (es) Inhibidores de la proteína tirosina fosfatasa
PE20171442A1 (es) Peptidos y combinacion de peptidos novedosos para su uso en inmunoterapia contra diversos tumores
AR065169A1 (es) Variantes de la proteina de fusion de actriib y usos de las mismas
PH12014501642A1 (en) Peptide vaccines for cancers expressing tumor-associated antigens
EA201290557A1 (ru) Пептидный аналог оксинтомодулина
EP2496245A4 (en) ANALOG OF PITUTIC ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHOD OF USE THEREOF
WO2013013085A3 (en) Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis
HK1213916A1 (zh) 有生物學活性的、含 -端精氨酸的肽
EP2598158A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING A PEPTIDE / PHOSPHOLIPID COMPLEX OF APOLIPOPROTEINS
RU2022100555A (ru) Новый пептид
SG11202112276RA (en) Novel peptide compound or pharmaceutically acceptable salt thereof
BR112015013708A2 (pt) polipeptídeo compreendendo uma proteína igf-1 humana, polinucleotídeo, composição farmacêutica e uso
EP2585455A4 (en) COMPOUNDS AND THEIR USE IN THE MODULATION OF THE CONCENTRATIONS OF VARIOUS AMYLOID BETA PEPTIDE ALLOYS
WO2015138784A3 (en) Compositions and methods for preventing or treating chronic lung allograft dysfunction and idiopathic pulmonary fibrosis
MX2009005090A (es) Metodos de promover la reparacion cardiaca usando factores de crecimiento fusionados a secuencias de ligadura de heparina.
AR089860A1 (es) Analogos de la grelina
CL2008003933A1 (es) Compuestos derivados de n-heterociclo-[1,2-a]-piridina-2-carboxamida; procedimiento de preparacion; composicion farmaceutica; utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas, inflamatorias, epilepsia, osteoporosis, tumores malignos, entre otras.
BR112018077219A2 (pt) matriz de peptídeo de automontagem para a prevenção de estenose esofágica após dissecção endoscópica
AR059088A1 (es) Administracion intraventricular de una proteina para esclerosis lateral amiotrofica
MX2011013972A (es) Peptido novedoso y su uso.
AR127062A1 (es) Composiciones y métodos para el tratamiento de trastornos metabólicos y hepáticos
AR098616A1 (es) Péptido para el tratamiento de hipoglicemia severa
MX2010010177A (es) Fragmentos de beta timosina mejorada.